Study
| Phase III, randomized, controlled, multicenter, open-label trial (DESTINY-Breast-02) |
| HER2-positive, previously received trastuzumab-emtansine, unresectable or metastatic breast cancer |
| Trastuzumab-deruxdeca (n=406) vs. SOC (n=202) |
Efficacy
| mPFS: 17.8 vs 6.9 mos, p<0.0001 |
| 12 months PFS: 62% vs. 27% |
| 24 months PFS: 42% vs 13% |
| mOS: 39.2 vs. 26.5 mos, p=0021 |
| 12 months OS: 89.4% vs.74.7% |
| 24 months OS: 65.9% vs.54.3% |
Safety
| Grade≥3 AEs: Neutropenia (11% vs 2%), Anemia (8% vs. 3%), nausea (7% vs 3%), palmar-plantar erythrodysesthesia (1% vs 10%), diarrhea (3% vs. 7%) |
Lancet Oncol, 20 APR, 2023
http://doi.org/10.1016/S0140-6736(23)00725-0
Reviewed by Elvin Chalabiyev, MD on May 20, 2023
